Across TCGA pan-cancer cohorts, LINC00670 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LINC00670 data layer compared with 17 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher LINC00670 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LINC00670 expression acts as an unfavorable survival marker.
SARC and ESCA are the cancer types where LINC00670 Mutation most reproducibly stratifies survival.